Outcomes | N° of studies | N° of patients | N° and (%) of events | RR (efficacy) | 95% CI (efficacy) | p | Heterogeneity test |
---|---|---|---|---|---|---|---|
α-2a/α-2b | α-2a/α-2b | (Q;p;I2,%) | |||||
Rapid Virological Response | 1,374/1,355 | 186(13.5)/174(12.8) | 1.05 | 0.87–1.27 | 0.62 | 3.8;0.28;21.1 | |
Early Virological Response | 1,395/1,371 | 649(46.5)/572(38.4) | 1.12 | 1.03–1.22 | 0.011 | 7.58;0.14;42.8 | |
End of Treatment Response | 1,243/1,217 | 782(62.9)/627(51.5) | 1.22 | 1.14–1.31 | <0.0001 | 7.6;0.11;47.3 | |
921/879 | 544(59)/403(45.8) | 1.29 | 1.18–1.41 | <0.0001 | 8.37;0.08;52.1 | ||
Sustained Virological Response | 1,336/1,310 | 574(43)/521(39.8) | 1.08 | 0.99–1.18 | 0.098 | 9.97;0.08;49.8 | |
1,058/732 | 473(44.7)/306(41.8) | 1.08 | 0.97–1.20 | 0.19 | 10.9;0.053;54.2 | ||
1,014/972 | 406(40)/346(35.5) | 1.13 | 1.01–1.26 | 0.04 | 8.59;0.13;41.8 |